TikoMed’s ILB® inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studiesViken, Sweden – 13[th] September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company’s lead drug candidate ILB® to: 1. inhibit infection of human cells by the NL63 coronavirus assessed by immunofluorescence of viral particles; and 2. directly block the interaction of the SARS-CoV-2 viral spike protein with the ACE2 receptor; and 3. modulate the downstream consequences of viral infection including the